Just caught ANI's Q4 numbers and they came in pretty solid. The pharma company pulled in $247 million in revenue, which beat estimates by over 6% - not bad for a quarter. What caught my eye is the EPS surprise, up 17% versus what Wall Street was expecting. Year-over-year growth looks healthy at 29.6% for revenue.

Looking at the breakdown, their generic pharma segment is where the real action was - $100.76 million versus the $86 million analysts had penciled in. That's a strong beat on generics. Their rare disease division came in slightly light versus estimates, but the brands side (ILUVIEN, YUTIQ, Cortrophin Gel) mostly held their own. Total rare disease and brands revenue hit $143.59 million, up 34% year-over-year.

The stock's been down 5.9% over the past month though, so the market hasn't exactly celebrated the beat yet. ANI currently sits at a Zacks Rank 2 (Buy), which suggests there could be upside ahead if the company can sustain this momentum.